These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 35177859)

  • 1. Metabolomic and microbiome profiling reveals personalized risk factors for coronary artery disease.
    Talmor-Barkan Y; Bar N; Shaul AA; Shahaf N; Godneva A; Bussi Y; Lotan-Pompan M; Weinberger A; Shechter A; Chezar-Azerrad C; Arow Z; Hammer Y; Chechi K; Forslund SK; Fromentin S; Dumas ME; Ehrlich SD; Pedersen O; Kornowski R; Segal E
    Nat Med; 2022 Feb; 28(2):295-302. PubMed ID: 35177859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-omics study reveals that statin therapy is associated with restoration of gut microbiota homeostasis and improvement in outcomes in patients with acute coronary syndrome.
    Hu X; Li H; Zhao X; Zhou R; Liu H; Sun Y; Fan Y; Shi Y; Qiao S; Liu S; Liu H; Zhang S
    Theranostics; 2021; 11(12):5778-5793. PubMed ID: 33897881
    [No Abstract]   [Full Text] [Related]  

  • 3. Alterations of Gut Microbiome and Serum Metabolome in Coronary Artery Disease Patients Complicated With Non-alcoholic Fatty Liver Disease Are Associated With Adverse Cardiovascular Outcomes.
    Hu X; Zhou R; Li H; Zhao X; Sun Y; Fan Y; Zhang S
    Front Cardiovasc Med; 2021; 8():805812. PubMed ID: 35047580
    [No Abstract]   [Full Text] [Related]  

  • 4. Association of Coronary Artery Disease and Metabolic Syndrome: Usefulness of Serum Metabolomics Approach.
    Jing Z; Liu L; Shi Y; Du Q; Zhang D; Zuo L; Du S; Sun Z; Zhang X
    Front Endocrinol (Lausanne); 2021; 12():692893. PubMed ID: 34630321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut microbiota and metabolomics profiles in patients with chronic stable angina and acute coronary syndrome.
    Ahmad AF; Caparrós-Martin JA; Gray N; Lodge S; Wist J; Lee S; O'Gara F; Dwivedi G; Ward NC
    Physiol Genomics; 2024 Jan; 56(1):48-64. PubMed ID: 37811721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of metabolomic biomarkers in patients with diabetes mellitus and coronary artery disease.
    Karagiannidis E; Moysidis DV; Papazoglou AS; Panteris E; Deda O; Stalikas N; Sofidis G; Kartas A; Bekiaridou A; Giannakoulas G; Gika H; Theodoridis G; Sianos G
    Cardiovasc Diabetol; 2022 May; 21(1):70. PubMed ID: 35525960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of the severity of coronary artery disease with patients' metabolic profile- rationale, design and baseline patient characteristics of the CorLipid trial.
    Karagiannidis E; Sofidis G; Papazoglou AS; Deda O; Panteris E; Moysidis DV; Stalikas N; Kartas A; Papadopoulos A; Stefanopoulos L; Karvounis H; Gika H; Theodoridis G; Sianos G
    BMC Cardiovasc Disord; 2021 Feb; 21(1):79. PubMed ID: 33557756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effects of Moderate Alcohol Consumption on Circulating Metabolites and Gut Microbiota in Patients With Coronary Artery Disease.
    Zhao X; Zhou R; Li H; Fan Y; Sun Y; Hu X; Zhang S
    Front Cardiovasc Med; 2021; 8():767692. PubMed ID: 34796220
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of counterbalance between macrophage migration inhibitory factor and its inhibitor Gremlin-1 in patients with coronary artery disease.
    Müller II; Müller KA; Karathanos A; Schönleber H; Rath D; Vogel S; Chatterjee M; Schmid M; Haas M; Seizer P; Langer H; Schaeffeler E; Schwab M; Gawaz M; Geisler T
    Atherosclerosis; 2014 Dec; 237(2):426-32. PubMed ID: 25463068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anxiety disturbs the blood plasma metabolome in acute coronary syndrome patients.
    Wei H; Gu J; Jiang X; Deng N; Wu J; Zou L; Zhu Y; Tan B
    Sci Rep; 2021 Jun; 11(1):12897. PubMed ID: 34145340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut microbiota combined with metabolites reveals unique features of acute myocardial infarction patients different from stable coronary artery disease.
    Dong C; Yang Y; Wang Y; Hu X; Wang Q; Gao F; Sun S; Liu Q; Li L; Liu J; Tang Y; Zhang S; Wu C; Zhu H
    J Adv Res; 2023 Apr; 46():101-112. PubMed ID: 35750287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A metabolomic view of how the human gut microbiota impacts the host metabolome using humanized and gnotobiotic mice.
    Marcobal A; Kashyap PC; Nelson TA; Aronov PA; Donia MS; Spormann A; Fischbach MA; Sonnenburg JL
    ISME J; 2013 Oct; 7(10):1933-43. PubMed ID: 23739052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysbiosis signatures of gut microbiota in coronary artery disease.
    Zhu Q; Gao R; Zhang Y; Pan D; Zhu Y; Zhang X; Yang R; Jiang R; Xu Y; Qin H
    Physiol Genomics; 2018 Oct; 50(10):893-903. PubMed ID: 30192713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Untargeted high-resolution plasma metabolomic profiling predicts outcomes in patients with coronary artery disease.
    Mehta A; Liu C; Nayak A; Tahhan AS; Ko YA; Dhindsa DS; Kim JH; Hayek SS; Sperling LS; Mehta PK; Sun YV; Uppal K; Jones DP; Quyyumi AA
    PLoS One; 2020; 15(8):e0237579. PubMed ID: 32810196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Metabolites Associated with Onset of CAD in Diabetic Patients Using CE-MS Analysis: A Pilot Study.
    Omori K; Katakami N; Yamamoto Y; Ninomiya H; Takahara M; Matsuoka TA; Bamba T; Fukusaki E; Shimomura I
    J Atheroscler Thromb; 2019 Mar; 26(3):233-245. PubMed ID: 30068816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiographic severity of coronary artery disease and cardiovascular risk in acute coronary syndrome in patients with metabolic syndrome.
    Widecka K; Safranow K; Lewandowski M; Przybycień K; Gorący J; Kornacewicz-Jach Z
    Kardiol Pol; 2018; 76(3):662-668. PubMed ID: 29297191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A specific gut microbiota and metabolomic profiles shifts related to antidiabetic action: The similar and complementary antidiabetic properties of type 3 resistant starch from Canna edulis and metformin.
    Zhang C; Ma S; Wu J; Luo L; Qiao S; Li R; Xu W; Wang N; Zhao B; Wang X; Zhang Y; Wang X
    Pharmacol Res; 2020 Sep; 159():104985. PubMed ID: 32504839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Untargeted metabolomic analysis of coronary artery disease patients with diastolic dysfunction show disturbed oxidative pathway.
    Fatima T; Hashmi S; Iqbal A; Siddiqui AJ; Sami SA; Basir N; Bokhari SS; Sharif H; Musharraf SG
    Metabolomics; 2019 Jun; 15(7):98. PubMed ID: 31236740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut microbiota dysbiosis in stable coronary artery disease combined with type 2 diabetes mellitus influences cardiovascular prognosis.
    Tian R; Liu H; Feng S; Wang H; Wang Y; Wang Y; Liang L; Xu H; Xing H; Zhang S
    Nutr Metab Cardiovasc Dis; 2021 May; 31(5):1454-1466. PubMed ID: 33810955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The gut microbiota-related metabolite phenylacetylglutamine associates with increased risk of incident coronary artery disease.
    Ottosson F; Brunkwall L; Smith E; Orho-Melander M; Nilsson PM; Fernandez C; Melander O
    J Hypertens; 2020 Dec; 38(12):2427-2434. PubMed ID: 32665522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.